ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2017
For 2017, total revenues amounted to 540.3 (478.9) * MSEK, representing an increase of 13%.
Zinzino’s total revenues for the fourth quarter of 2017 amounted to 154,7 (144,5)* MSEK, corresponding to sales growth of 7% compared to the same period in 2016.
Most markets showed strong growth during the quarter. Germany increased by 110%. The newly established EU markets increased 109% in total. In the Baltic countries, the strong sales growth continued in Latvia which increased by 82%. The high turnover markets Sweden and Finland increased by 41% and 24% respectively during the fourth quarter.
* Comparative figures adjusted per the new accounting policy regarding currency-related income and expenses.
For more information:
Dag Bergheim Pettersen, CEO Zinzino, Tel. +47 93 22 57 00 www.zinzino.se
Pictures for publication free of charge: Marcus Tollbom, Tel. + 46 (0) 70-190 03 12
Certified Adviser: Erik Penser, Bank Aktiebolag
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 15.00 on 10th of January 2018.
Zinzino Nordic AB (publ.) is a direct sales company that operates throughout Europe and North America. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActie Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 33 markets across Europe and North America. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, and in Florida, USA. Zinzino is a public company and its shares are listed on Nasdaq First North. In 2016, Zinzino was recognized with the award ‘’Superföretag 2015’’ by Veckans Affärer and the ‘’Gazelle’’ award by Dagens Industri.